Flagship-founded single-cell analysis company Cellarity is using its $123 million series B round to advance seven preclinical programs across four complex disease areas, turning the corner from a scientific discovery shop to an integrated drug discovery...

Another member of biotech’s founding generation is preparing to move on. Ionis Executive Chairman Stanley Crooke, who founded Ionis as Isis in 1989 and over the next three decades was unyielding in his decidation to...

While the pandemic has put much of normal life on hold, the biotech industry has continued to hum along, funding and advancing R&D while simultaneously ushering the world into the post-COVID era one...

With the approval of Oxlumo to treat primary hyperoxaluria, Alnylam is aiming to accelerate patient access to the ultra-rare disease therapy by building on the performance- and prevalence-based pricing...

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more complex, highly prevalent settings. On Thursday, Syncona Ltd. (LSE:SYNC) launched its sixth...

With interim COVID-19 vaccine efficacy data from BioNTech and Pfizer outstripping the field’s expectations, the results have set a high bar for what could be a rapid wave of readouts accelerated by surges...

A VC syndicate that backed IFM and serial dealmaker Gary Glick has launched precision oncology start-up Scorpion, where Glick will be president and CEO, with $108 million in series A funding. Scorpion...

Jan van de Winkel sees a strong future for data sharing and more master protocol trials, fueled by increasing adoption of digital sciences, as companies turn the collaboration they’ve shown in COVID-19 into longer-term productive...

A collaboration between JLABS and BARDA gives the government agency access to start-ups that it needs to fast track new, innovative COVID-19 therapies and diagnostics it otherwise would struggle...

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...